Virax Biolabs Group Ltd (VRAX) Enterprise Value (2021 - 2023)
Virax Biolabs (VRAX) posted Enterprise Value of -$9.4 million for Q1 2023, down 42888.32% on a QoQ basis from -$21756.0 in Q1 2022, and down 42888.32% year-over-year from N/an in Q1 2022.
Virax Biolabs (VRAX) has 3 years of Enterprise Value data on file, last reported at -$9.4 million in Q1 2023.
- In Q1 2023, Enterprise Value fell 42888.32% year-over-year to -$9.4 million; the TTM figure through Mar 2023 stood at -$9.4 million (down 42888.32% YoY), while the FY2023 annual figure was -$9.4 million, down 42888.32% from the prior year.
- Enterprise Value fell to -$9.4 million in Q1 2023, from -$21756.0 in the prior quarter.
- Across five years, Enterprise Value topped out at -$17621.0 in Q1 2021 and bottomed at -$9.4 million in Q1 2023.
- A 3-year average of -$3.1 million and a median of -$21756.0 in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value declined 23.47% — and 2023, when it slumped 42888.32%.
- Year by year, Enterprise Value stood at -$17621.0 in 2021, then slipped by 23.47% to -$21756.0 in 2022, then slumped by 42888.32% to -$9.4 million in 2023.
- The last three Enterprise Value figures came in at -$9.4 million (Q1 2023), -$21756.0 (Q1 2022), and -$17621.0 (Q1 2021), per Business Quant data.
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -9.35 Mn |
| Mar 31, 2022 | -21,756.00 |
| Mar 31, 2021 | -17,621.00 |